The biopharmaceutical enterprise FORT (part of the Marathon Group and the National Immunobiological Company (Natsimbio) holding) has exported its first 1.1 million doses of influenza vaccines.
In 2020, FORT exported vaccines to Belarus, Moldova, Kyrgyzstan, Turkmenistan and Uzbekistan. In the overall structure of supplies, the largest volume (over 90%) was accounted by quadrivalent vaccine "Ultrix Quadri".
Ultrix Quadri is the latest domestic development created by FORT biopharmaceutical enterprise. The vaccine provides active immunization against four strains of influenza virus - two subtypes of virus A and two subtypes of virus B. "Ultrix Quadri" is produced using a full cycle technology in compliance with international Good Manufacturing Practice (GMP) standards.
“Our production facilities allow to produce 50 million doses of tetravalent vaccine per year. This puts FORT on a par with the world's largest manufacturers. Amid the current epidemic, FORT influenza vaccines are already being used for immunoprophylaxis of the population of five countries, in addition to Russia. Interest from foreign partners is growing. We estimate the potential demand at tens of millions of doses annually. At the same time, meeting the needs of national healthcare will always be our absolute priority”, said Andrey Zagorsky, General Director of the Natsimbio holding.
Work is underway to carry out the procedure for prequalification of the enterprise by the World Health Organization. This will increase the export potential of Russian influenza vaccines, including the latest Ultrix Quadri, and will open up opportunities for work in Europe, North America and Southeast Asia.
